Miglustat

證據等級: L5

預測適應症: 10 個

Miglustat: From Type 1 Gaucher Disease to Tay-Sachs Disease

One-Sentence Summary

Miglustat is an oral glucosylceramide synthase (UGCG) inhibitor originally developed as substrate reduction therapy for Type 1 Gaucher disease and later extended to Niemann-Pick disease type C. Among 10 TxGNN-predicted indications, Tay-Sachs disease is the only candidate backed by actual research — 5 clinical trials and 20 publications, including a completed randomized controlled trial. The remaining 9 candidates (highest TxGNN scores) have no supporting evidence and are held at model-prediction-only status.

Quick Overview

Item	Content
Original Indication	Type 1 Gaucher disease (literature-sourced; original_indications field empty in this dataset; drug not locally licensed)
Predicted New Indication	Tay-Sachs Disease (GM2 gangliosidosis)
TxGNN Prediction Score	99.75% (rank 6,820 of model output)
Evidence Level	L2
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Miglustat is an imino sugar that inhibits glucosylceramide synthase (UGCG), the first committed enzyme in glycosphingolipid biosynthesis. This mechanism — substrate reduction therapy (SRT) — lowers the production rate of glycosphingolipids so that residual catabolic enzyme activity in a deficient patient can keep pace, reducing pathological lysosomal storage. This mechanism is already clinically validated: miglustat is licensed for Gaucher disease and Niemann-Pick type C, both lysosomal storage disorders involving glycosphingolipid accumulation.

Tay-Sachs disease is caused by hexosaminidase A deficiency, leading to accumulation of GM2 ganglioside — a downstream product of the same glycosphingolipid biosynthetic pathway that UGCG initiates. Reducing upstream substrate flux via UGCG inhibition is therefore mechanistically well-aligned with Tay-Sachs pathophysiology, unlike several of the model’s other top-ranked predictions (e.g., cholesteryl ester storage disease, adrenal neoplasm), which involve unrelated lipid or unclear pathways and show weak or no mechanistic linkage per the evidence pack’s own rationale notes.

This mechanistic logic is reflected in the trial record: multiple sponsor-run pharmacokinetic/safety studies and one randomized controlled trial in late-onset Tay-Sachs disease were conducted specifically because of this shared pathway, making Tay-Sachs disease the best-supported candidate among the ten TxGNN predictions despite not having the single highest similarity score.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03822013	Phase 3	Terminated	30	Evaluated miglustat’s effect on neurological and systemic symptoms in infantile Sandhoff/Tay-Sachs disease; trial terminated before completion
NCT00672022	Phase 3	Completed	10	PK, safety and tolerability of Zavesca (miglustat) in infantile-onset GM2 gangliosidosis (single and steady-state oral doses)
NCT00418847	Phase 2	Completed	5	PK and tolerability of Zavesca (miglustat) in juvenile GM2 gangliosidosis; single/multiple oral doses
NCT02030015	Phase 4	Terminated	16	“Syner-G” combination of miglustat plus ketogenic diet in infantile/juvenile gangliosidoses; terminated before completion
NCT07399704	Phase 2	Recruiting	21	Long-term safety/efficacy study of nizubaglustat (a newer investigational SRT agent, not miglustat) in GM2 gangliosidosis/NPC patients, including those transitioning from prior miglustat treatment — supports disease feasibility but is not direct miglustat evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19346952	2009	RCT	Genetics in Medicine	12-month randomized controlled study (with 24-month extension) evaluating miglustat safety and efficacy in late-onset Tay-Sachs/GM2 gangliosidosis
37209042	2023	Systematic Review	European Journal of Neurology	Systematic review of miglustat efficacy and safety across GM2 gangliosidosis studies; notes prior inconsistent results
32867370	2020	Review	Int J Mol Sciences	Overview of GM2 gangliosidoses clinical features, pathophysiology and current therapies including substrate reduction
30524313	2018	Review	Frontiers in Physiology	Survey of new therapeutic approaches to Tay-Sachs disease
18618288	2008	Cohort/Pilot	J Inherited Metabolic Disease	Neurocognitive testing pilot study in late-onset Tay-Sachs disease as an outcome measure for therapeutic trials
16434676	2006	Cohort (open-label)	Neurology	Substrate reduction therapy with miglustat in two infantile Tay-Sachs patients; could not arrest neurologic decline, but CSF drug levels and macrocephaly prevention observed
28476546	2017	Cohort/Natural history	Molecular Genetics and Metabolism	Natural history timeline of infantile gangliosidoses; notes miglustat SRT tried but limited by GI side effects
12808890	2003	Review (drug profile)	Curr Opin Investig Drugs	Drug profile confirming miglustat’s approved use in Gaucher disease and development for Tay-Sachs, Fabry, and Niemann-Pick C
30743792	2009	Review	Expert Rev Endocrinol Metab	Reviews substrate-reduction therapy with miglustat for CNS-affecting glycosphingolipid storage disorders
9572057	1998	Review (basic research)	Molecular Medicine Today	Early review of GM2 gangliosidosis biology and potential treatment strategies

US Market Information

Currently not marketed in this jurisdiction — 0 NDA/license records on file.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Tay-Sachs disease is supported by L2-level evidence — a completed randomized controlled trial plus multiple completed Phase 2/3 pharmacokinetic studies — and a mechanistically direct link (shared UGCG/glycosphingolipid pathway) to miglustat’s already-approved indications. However, two of the five trials were terminated early and enrollments are very small (n=5–30), so efficacy remains unconfirmed rather than established.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official prescribing information (warnings, contraindications) before any S1 safety review can proceed
Resolve DG002 (High): confirm full mechanism-of-action documentation via DrugBank/label review
Investigate reasons for early termination of NCT03822013 and NCT02030015 (efficacy failure vs. enrollment/funding issues)
Since the drug holds no local marketing authorization, define the regulatory/import pathway before any clinical use is considered
Given very small trial sizes, prioritize a pooled/meta-analytic reassessment or a new adequately powered trial before advancing past S2
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.